Market Future For Depression Therapy And Anxiety Disorders


With depression and anxiety disorders becoming a considerable public health problem, increased efforts are being put in motion to reduce their impact. A big part of this undertaking entails the use of antidepressants and anxiolytics, which will display well for the worldwide depression therapy and anxiety disorder market.

However, the report notes that the market for depression therapy and anxiety disorders will be confined to a great degree by leading medications in the market facing expiration of patents. This is compounded by a relatively dry pipeline of depression therapy and anxiety disorder medications. The report also notes that medication-resistant mental conditions could pose a setback to the growth of the global depression therapy and anxiety disorder market.

Information that was released by the World Health Organization in Oct. 2015 stated that over 350 million people across all ages suffer from depression and anxiety disorders. Given the possibility of depression leading to suicide, healthcare agencies are putting forth stronger efforts to tackle the burden using effective medications and therapies. This should be a high-impact driver for the global depression therapy and anxiety disorder market, TMR said.

TMR researchers have suggested players in the market to focus on enhancing and distribution networks in emerging economies and developing herbal treatments as an alternative to treat anxiety disorders and depression. Countries such as China, Mexico, South Africa, India, Singapore, and Brazil have advantageous potential for generic pharmaceuticals, the report stated.

For an in-depth study, the report segments the global depression therapy and anxiety disorder market on the basis of pipeline analysis, geography, and drug class. Based on drug class, the market is organized into selective serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), monoamine oxidase inhibitors (MAOIs), benzodiazepine, and beta-blockers.


Please enter your comment!
Please enter your name here